A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • STATUS
    Recruiting
  • sponsor
    Theracos
Updated on 8 November 2020

Summary

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Description

Patients with type 2 diabetes have increased risk of developing cardiovascular complications. Improved control of hyperglycemia or blood pressure reduces the risk of diabetic complications Administration of bexagliflozin, a potent SGLT2 inhibitor, has been shown to be well tolerated and to decrease HbA1c in subjects with type 2 diabetes. Study THR-1442-C-476 is designed to demonstrate that bexagliflozin also improves glucose control in patients at higher risk of cardiovascular events. There may be additional benefits of bexagliflozin of weight loss and reduction of blood pressure.

Details
Clinical Study IdentifierTX145097
SponsorTheracos
Last Modified on8 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 40 yrs and 0 yrs?
Gender: Male or Female
Age ≥ 40 years old
Subjects with a diagnosis of diabetes, type 2 and HbA1c values of 7.5 – 11%
Stable diabetes treatment regimen for the past 3 months
Subjects who present with at least one of the following cardiovascular histories
Myocardial infarction (heart attack)
Stroke
Prior coronary artery bypass grafting or coronary stent
Congestive heart failure
Multiple cardiovascular risk factors including Age ≥ 55 years, diabetes duration of = 10 years, uncontrolled hypertension, current smoking, chronic kidney disease, or low HDL cholesterol
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note